Travere Therapeutics

FSGS And IgA Nephropathy Expansion Will Transform Market Reach

AnalystConsensusTarget

Not Invested

Consensus Narrative from 14 Analysts

Published

25 Apr 25

Updated

08 Aug 25

AnalystConsensusTarget's Fair Value

US$34.40

47.5% undervalued

08 Aug

US$18.05

111.6%

4.7%

Author's Valuation

US$34.4

47.5% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates1

Shared on01 May 25
Fair value Increased 0.39%

AnalystConsensusTarget Fair Value

US$34.4

47.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

25.00%

Biotech revenue growth rate

12.62%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.04%

Calculation

US$212.23m

Earnings '28

21.66x

PE Ratio '28

US$4.60b

Market Cap '28

US$4.60b

Market Cap '28

109.15m

No. shares '28

US$42.10

Share Price '28

US$42.10 Share Price '28

Discounted to 2025 @ 7.02% p.a.

US$34.35

Fair Value '25

FSGS And IgA Nephropathy Expansion Will Transform Market Reach

Shared on01 May 25Fair value Increased 0.39%

Shared on01 May 25
Fair value Increased 0.39%